Sharon Larkin
Directeur/Membre du Conseil chez SENSEONICS HOLDINGS, INC.
Fortune : 227 393 $ au 31/05/2024
Profil
Sharon D.
Larkin is currently the Director at Senseonics, Inc. and an Independent Director at Senseonics Holdings, Inc. Previously, she worked at Abbott Laboratories as the Divisional VP-HR & Medical Devices Group from 2011 to 2015.
She also served as the Senior VP-Human Resources & Administration at Assertio Therapeutics, Inc. from 2017 to 2020.
Ms. Larkin completed her undergraduate degree at Georgia Institute of Technology.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 22/05/2024 | 528 820 ( 0,10% ) | 227 393 $ | 31/05/2024 |
Postes actifs de Sharon Larkin
| Sociétés | Poste | Début |
|---|---|---|
| SENSEONICS HOLDINGS, INC. | Directeur/Membre du Conseil | 08/12/2021 |
Senseonics, Inc.
 Senseonics, Inc. Electronic ComponentsElectronic Technology Senseonics, Inc. develops transformative glucose monitoring products. It develops Senseonics continuous glucose monitoring system, an implantable continuous glucose monitoring system, which includes a miniaturized sensor and receiver that is inserted into the subcutaneous space under the skin to wirelessly transmit glucose levels to an external receiver. The company was founded by Michael James Barrett and Arthur E. Colvin in 1996 and is headquartered in Germantown, MD. | Directeur/Membre du Conseil | 01/12/2021 |
Anciens postes connus de Sharon Larkin
| Sociétés | Poste | Fin |
|---|---|---|
Assertio Therapeutics, Inc.
 Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Directeur Administratif | 01/01/2020 |
| ABBOTT LABORATORIES | Responsable des Ressources Humaines | 01/09/2015 |
Formation de Sharon Larkin
| Georgia Institute of Technology | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| SENSEONICS HOLDINGS, INC. | Electronic Technology |
| Entreprise privées | 2 |
|---|---|
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Health Technology |
Senseonics, Inc.
Senseonics, Inc. Electronic ComponentsElectronic Technology Senseonics, Inc. develops transformative glucose monitoring products. It develops Senseonics continuous glucose monitoring system, an implantable continuous glucose monitoring system, which includes a miniaturized sensor and receiver that is inserted into the subcutaneous space under the skin to wirelessly transmit glucose levels to an external receiver. The company was founded by Michael James Barrett and Arthur E. Colvin in 1996 and is headquartered in Germantown, MD. | Electronic Technology |
